Propranolol in the prevention of the first hemorrhage from esophagogastric varices: A multicenter, randomized clinical trial

Hepatology

Volumn 13, Issue 5, 1991, Pages 902-912

  Conn, Harold O ^a   Grace, Norman D ^b   Bosch, Jaime ^c   Groszmann, Roberto J ^a   Rodés, Joan ^c   Wright, Steven C ^b   Matloff, Daniel S ^b   Garcia‐Tsao, Guadalupe ^a   Fisher, Rosemarie L ^a   Navasa, Miguel ^c   Drewniak, Steven J ^b   Atterbury, Colin E ^a   Bordas, Jose M ^c   Lerner, Emanuel ^a   Bramante, Christina ^b  

^a YALE UNIVERSITY SCHOOL OF MEDICINE   (United States)

^b TUFTS UNIVERSITY SCHOOL OF MEDICINE   (United States)

^c UNIVERSITY OF BARCELONA   (Spain)

Author keywords

[No Author keywords available]

Indexed keywords

PROPRANOLOL;

ADULT; AGED; ALCOHOLISM; ARTICLE; CONTROLLED STUDY; ESOPHAGUS VARICES; ESOPHAGUS VARICES BLEEDING; FEMALE; HUMAN; LIVER CIRRHOSIS; MAJOR CLINICAL STUDY; MALE; PATIENT COMPLIANCE; PORTAL HYPERTENSION; PRIORITY JOURNAL; STOMACH VARICES; SURVIVAL;

BLOOD PRESSURE; DOUBLE-BLIND METHOD; ESOPHAGEAL AND GASTRIC VARICES; FEMALE; GASTROINTESTINAL HEMORRHAGE; HEART RATE; HUMAN; HYPERTENSION, PORTAL; LIVER CIRRHOSIS, ALCOHOLIC; MALE; MIDDLE AGE; PATIENT COMPLIANCE; PROPRANOLOL; SUPPORT, NON-U.S. GOV'T; SUPPORT, U.S. GOV'T, NON-P.H.S.;

EID: 0025830767     PISSN: 02709139     EISSN: 15273350     Source Type: Journal    
DOI: 10.1002/hep.1840130517     Document Type: Article

References (56)

1. The course of patients after variceal hemorrhage
2. Variceal hemorrhage
3. Cirrhosis
4. Main causes of death in cirrhosis
5. Prophylactic portacaval anastomosis in cirrhotic patients with esophageal varices: interim results, with suggestions for subsequent investigations
6. A clinical investigation of the portacaval shunt
7. A controlled study of the prophylactic portacaval shunt
8. Prophylactic portacaval anastomosis: a tale of two studies
9. Prophylactic endoscopic sclerosing treatment of the esophageal wall in varices: a prospective randomized trial
10. Prophylactic endoscopic sclerotherapy of oesophageal varices: a prospective controlled study
11. Prophylactic sclerotherapy of high‐risk esophageal varices: results of a multicentric prospective controlled trial
12. Prophylactic sclerosing of esophageal varices: results of a prospective controlled study
13. Prophylaktische osophagusvarizensklerosierung
14. Prophylactic sclerotherapy before the first episode of variceal hemorrhage in patients with cirrhosis
15. Prophylactic endoscopic sclerotherapy of oesophageal varices in liver cirrhosis: a multicentre prospective controlled randomised trial in Vienna
16. Prophylactic sclerotherapy of large esophageal varices
17. Long term follow‐up of a controlled trial of prophylactic sclerotherapy for oesophageal varices in England [Abstract]
18. Prophylactic sclerotherapy for esophageal varices in alcoholic liver disease: results of a VA cooperative randomized trial [Abstract]
19. The Italian Multicenter Project for Propranolol in Prevention of Bleeding. Propranolol for prophylaxis of bleeding in cirrhotic patients with large varices: a multicenter, randomized clinical trial
20. A randomized trial comparing prophylactic (PS) and therapeutic endoscopic sclerotherapy (TS) in cirrhotic patients with large esophageal varices and no previous hemorrhage [Abstract]
21. A randomized controlled study of propranolol for prevention of recurrent gastrointestinal bleeding in patients with cirrhosis: a final report
22. Nadolol for prevention of variceal rebleeding in cirrhosis: a controlled clinical trial
23. Reduction in early recurrence of variceal bleeding by propranolol
24. β‐Blockade prevents recurrent gastrointestinal bleeding in well‐compensated patients with alcoholic cirrhosis: a multicenter randomized controlled trial
25. Randomized controlled study of propranolol for prevention of recurrent esophageal varices bleeding in patients with cirrhosis
26. Propranolol in the prevention of recurrent variceal hemorrhage in cirrhotic patients
27. Controlled trial of propranolol to prevent recurrent variceal bleeding in patients with non‐cirrhotic portal fibrosis
28. Controlled trial of propranolol for the prevention of recurrent variceal hemorrhage in patients with cirrhosis
29. Propranolol for the prevention of recurrent variceal hemorrhage: a controlled trial
30. Etude controlee du propranolol dans la prevention des recidives hemorrhagiques chez les patients cirrhotiques
31. Short‐term effects of propranolol on portal venous pressure
32. Hemodynamic events in a prospective randomized trial of propranolol vs. placebo in the prevention of the first variceal hemorrhage
33. Surgery and portal hypertension
34. A peek at the Child‐Turcotte classification
35. Portal pressure, presence of gastroesophageal varices and bleeding
36. An improved approximate formula for calculating sample sizes for comparing two binomial distributions
37. The role of propranolol in congestive gastropathy of portal hypertension
38. Gastric mucosal vascular ectasias causing bleeding in cirrhosis: a distinct entity associated with hypergastrinemia and low serum levels of pepsinogen I
39. Multicenter Study Group. Propranolol in the prevention of first upper gastrointestinal tract hemorrhage in patients with cirrhosis of the liver and esophageal varices
40. The Italian Multicenter Project for Propranolol in Prevention of Bleeding. Propranolol for prophylaxis of bleeding in cirrhotic patients with large varices: a multi‐center randomized clinical trial
41. Nadolol for preventing the first gastrointestinal bleeding
42. Nadolol for prophylaxis of gastrointestinal bleeding in patients with cirrhosis: a randomized trial
43. Complexity and contradiction in clinical trial research
44. Adrenocorticosteroid administration and peptic ulcer: a critical analysis
45. Effect of beta blockade and beta stimulation on stage fright
46. Lactate, beta‐antagonists, beta‐blockers and anxiety
47. Ideal treatment of portal hypertension in1985
48. Comparison of the effects of a cardioselective and a nonselective B‐blocker on portal hypertension in patients with cirrhosis
49. Therapeutic controversies and randomised controlled trials (RCTs): prevention of bleeding and rebleeding in cirrhosis
50. Vasopressin and nitroglycerin in the treatment of bleeding varices: the bottom line
51. A hepatologist's view of variceal bleeding
52. Propranolol for prevention of first esophageal variceal hemorrhage (EVH): a lifetime commitment [Abstract]
53. Effects of nadolol treatment on renal and hepatic hemodynamics and function in cirrhotic patients with portal hypertension